UNITED LAB (The United Laboratories International Holdings Limited) announced the completion of a 24-week Phase II clinical trial for its Class 1 innovative drug UBT251 Injection in Chinese adults with Type 2 diabetes.
The randomized, double-blind study enrolled 211 patients managed by lifestyle modification with or without metformin. Participants received once-weekly subcutaneous UBT251 at 2 mg, 4 mg, or 6 mg, placebo, or the active comparator semaglutide 1 mg.
Primary endpoint • UBT251 achieved a mean glycated hemoglobin (HbA1c) reduction of up to 2.16 %, outperforming semaglutide at 1.77 % and placebo at 0.66 %.
Key secondary outcomes • Mean body-weight loss reached 9.8 % with UBT251, versus 4.8 % for semaglutide and 1.4 % for placebo. • Additional benefits over placebo were observed in waist circumference, blood pressure, and lipid profiles.
Safety and tolerability • Adverse events were consistent with the known profile of triple-G agonists, with no new safety signals reported.
Next steps • The favourable Phase II data support advancement to a Phase III trial in Chinese patients with Type 2 diabetes; preparations are underway.
Drug profile • UBT251 is a long-acting triple agonist of GLP-1, GIP, and glucagon receptors. The company holds approvals to study the molecule in China and the United States for Type 2 diabetes, overweight/obesity, chronic kidney disease, and MASH. UNITED LAB is the first in China and second globally to enter clinical trials with a chemically synthesized long-acting triple agonist. • In March 2025 UNITED LAB and subsidiary United Bio-Technology (Hengqing) Co., Ltd. entered an exclusive licence agreement with Novo Nordisk A/S covering UBT251.
The Board under Chairman Tsoi Hoi Shan released the announcement on 25 March 2026.
Comments